Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.
Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...
Cybin wins new Buy from Guggenheim: potential to challenge J&J’s Spravato cited
Cybin (CYBN) stock earns Guggenheim's Buy rating with a $35 target, as the firm cites blockbuster potential for CYB003 in line with J&J's (JNJ) Spravato. Read more here.